Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Medeye Associates

Neither a doctor nor a teaching hospital

Research payments

$852,997

101 payments

Through program year 2025, Medeye Associates is reported as receiving $852,997 in research payments, across 101 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $118,086 28
2024 Research $159,359 5
2023 Research $130,089 17
2022 Research $85,808 8
2021 Research $177,440 5
2020 Research $26,247 4
2019 Research $155,968 34

Breakdown

Who paid Research payments · program years 2019–2025
  1. Amgen Inc. $205,003 6 payments
  2. Novartis Pharmaceuticals Corporation $165,974 13 payments
  3. Regeneron Pharmaceuticals, Inc. $152,296 18 payments
  4. Roche TCRC, Inc. $144,497 9 payments
  5. EyePoint Pharmaceuticals US, Inc. $103,729 5 payments
  6. AbbVie, Inc. $40,732 9 payments
  7. Allergan Inc. $27,762 18 payments
  8. Alexion Pharmaceuticals, Inc. $6,785 2 payments
  9. Hexal AG $4,500 1 payment
  10. Boehringer Ingelheim International GmbH $1,569 19 payments
Studies the money was for Research payments · program years 2019–2025
  1. ABP 938 Global Phase 3 Study $163,444 4 payments
  2. A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients With Moderately Severe to Severe Nonproliferative Diabetic Retinopathy $141,458 15 payments
  3. A Randomized, Active-Controlled, Subject and Investigator-Masked, Multiple Dose Proof-Of-Concept Study of Intravitreal Lka651 in Patients With Diabetic MacUlar Edema $115,103 5 payments
  4. Entry Into Human of Ro7497372 in Participants With Diabetic MacUlar Edema $105,529 5 payments
  5. A Phase 2, Multicenter, Prospective, Double-masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Sham for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR) $78,828 2 payments
  6. A 96-Week, Two-Arm, Randomized, Single-Masked, Multi-Center, Phase III Study Assessing the Efficacy and Safety of Brolucizumab 6 MG Compared to Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy $50,421 7 payments
  7. ABP 938 Global P3 Study $41,559 2 payments
  8. Oral Treatment of NPDR $38,968 4 payments
  9. Long-term Safety and Efficacy Extension Trial of Bimatoprost SR $31,892 3 payments
  10. A 2-year Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD $14,488 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record